MANNKIND CORPMNKDEarnings & Financial Report
MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.
Revenue
$82.1M
Gross Profit
$77.6M
Operating Profit
$18.9M
Net Profit
$8.0M
Gross Margin
94.5%
Operating Margin
23.0%
Net Margin
9.7%
YoY Growth
17.2%
EPS
$0.03
MANNKIND CORP Q3 FY2025 Financial Summary
MANNKIND CORP reported revenue of $82.1M (up 17.2% YoY) for Q3 FY2025, with a net profit of $8.0M (down 30.9% YoY) (9.7% margin). Cost of goods sold was $4.5M, operating expenses totaled $58.7M.
Key Financial Metrics
| Total Revenue | $82.1M |
|---|---|
| Net Profit | $8.0M |
| Gross Margin | 94.5% |
| Operating Margin | 23.0% |
| Report Period | Q3 FY2025 |
Revenue Breakdown
MANNKIND CORP Q3 FY2025 revenue of $82.1M breaks down across 4 segments, led by Product Revenue at $48.3M (58.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Product Revenue | $48.3M | 58.8% |
| License And Service | $26.5M | 32.3% |
| V Go | $3.8M | 4.6% |
| UTCSA | $3.1M | 3.7% |
MANNKIND CORP Revenue by Segment — Quarterly Trend
MANNKIND CORP revenue by segment across the last 4 reported quarters, showing how each business line (such as Product Revenue and License And Service) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Product Revenue | — | $48.3M | — | — |
| License And Service | — | $26.5M | $22.8M | $29.4M |
| V Go | $4.3M | $3.8M | $4.1M | $4.1M |
| UTCSA | — | $3.1M | — | — |
MANNKIND CORP Annual Revenue by Year
MANNKIND CORP annual revenue history includes year-by-year totals (for example, 2025 revenue was $349.0M).
| Year | Annual Revenue |
|---|---|
| 2025 | $349.0M |
| 2024 | $285.5M |
| 2023 | $199.0M |
MANNKIND CORP Quarterly Revenue & Net Profit History
MANNKIND CORP results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $112.0M | +45.8% | $-15.9M | -14.2% |
| Q3 FY2025 | $82.1M | +17.2% | $8.0M | 9.7% |
| Q2 FY2025 | $76.5M | +5.7% | $668.0K | 0.9% |
| Q1 FY2025 | $78.4M | +18.2% | $13.2M | 16.8% |
| Q4 FY2024 | $76.8M | +31.3% | $7.4M | 9.7% |
| Q3 FY2024 | $70.1M | +36.7% | $11.6M | 16.5% |
| Q2 FY2024 | $72.4M | +48.9% | $-2.0M | -2.8% |
| Q1 FY2024 | $66.3M | +63.1% | $10.6M | 16.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $66.3M | $72.4M | $70.1M | $76.8M | $78.4M | $76.5M | $82.1M | $112.0M |
| YoY Growth | 63.1% | 48.9% | 36.7% | 31.3% | 18.2% | 5.7% | 17.2% | 45.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $480.9M | $443.8M | $464.2M | $393.8M | $410.1M | $411.7M | $494.6M | $792.2M |
| Liabilities | $710.8M | $669.6M | $674.1M | $472.7M | $468.8M | $466.7M | $539.2M | $843.2M |
| Equity | $-230.0M | $-225.8M | $-209.9M | $-78.8M | $-58.6M | $-55.0M | $-44.6M | $-51.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $6.7M | $3.8M | $9.3M | $22.6M | $-6.4M | $8.9M | $23.6M | $-8.0M |